Substance / Medication

Axitinib

SNOMED 427882000 UMLS C1700874

Overview

Active Ingredient

axitinib

RxNorm CUI

1242999

Labeler: Pfizer Laboratories Div Pfizer IncUpdated: 2025-02-19T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Renal cell carcinoma

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.

Edwards Steve J, Wakefield Victoria, Cain Peter et al. · Health Technol Assess · 2018

PMID: 29393024Meta-AnalysisFull text (PMC)

Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.

Abdel-Rahman Omar, Fouad Mona · Crit Rev Oncol Hematol · 2014

PMID: 25028151Meta-Analysis

Pharmacokinetics of single-agent axitinib across multiple solid tumor types.

Tortorici Michael A, Cohen Ezra E W, Pithavala Yazdi K et al. · Cancer Chemother Pharmacol · 2014

PMID: 25336084Meta-Analysis

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

Fischer Alyssa, Wu Shenhong, Ho Alan L et al. · Invest New Drugs · 2013

PMID: 23345001Meta-Analysis

Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.

Qi Wei-Xiang, He Ai-Na, Shen Zan et al. · Br J Clin Pharmacol · 2013

PMID: 23617405Meta-AnalysisFull text (PMC)

Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.

Brennan Meghan, Williams J Andrew, Chen Ying et al. · Eur J Clin Pharmacol · 2012

PMID: 22170007Meta-Analysis

Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis.

Zurita Amado J, Tidwell Rebecca S, Chapin Brian F et al. · Eur Urol Oncol · 2025

PMID: 40651932RCT

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Yan X Q, Ye M J, Zou Q et al. · Ann Oncol · 2024

PMID: 37872020RCT

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.

Tomita Y, Motzer R J, Choueiri T K et al. · ESMO Open · 2022

PMID: 35397432RCTFull text (PMC)

Bedke Jens, Rini Brian I, Plimack Elizabeth R et al. · Eur Urol · 2022

PMID: 35843776RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Axitinib (substance)
SNOMED CT: 427882000
UMLS CUI: C1700874
RxNorm CUI: 1242999
Labeler: Pfizer Laboratories Div Pfizer Inc

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.